Method for expressing and purifying protein by using csq-tag
US-2024209046-A1 · Jun 27, 2024 · US
Novel antigen peptide and uses thereof
US2016331818A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016331818-A1 |
| Application number | US-201514963308-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 9, 2015 |
| Priority date | Jun 1, 2011 |
| Publication date | Nov 17, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
First claim
Opening claim text (preview).
1 - 11 . (canceled) 12 . A method for producing genetically modified T lymphocytes, said method comprising the steps of: (a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from a subject with at least one antigen peptide, wherein said antigen peptide comprises an amino acid motif having an amino acid sequence: (SEQ ID NO: 2) VLVPPLPSL, wherein the amino acid sequence of the amino acid motif may differ from VLVPPLPSL by 1, 2 or 3 amino acids, (b) enriching the population of T lymphocytes specific for the antigen peptide(s) used in (a), and (c) optionally cloning said population of T lymphocytes specific for the antigen peptide(s) used in (a). 13 - 14 . (canceled) 15 . A method of treating cancer in a subject in need thereof, comprising the steps of (a) stimulating PBMCs or tumor infiltrating lymphocytes obtained from the subject with at least one antigen peptide, wherein said antigen peptide comprises an amino acid motif having an amino acid sequence: (SEQ ID NO: 2) VLVPPLPSL, wherein the amino acid sequence of the amino acid motif may differ from VLVPPLPSL by 1, 2 or 3 amino acids, (b) enriching the population of genetically modified T lymphocytes specific for the antigen peptide(s) used in (a), (c) optionally cloning said population of genetically modified T lymphocytes specific for the antigen peptide(s) used in (a), and (d) administering to the subject a therapeutically effective amount of a composition for adoptive therapy comprising the genetically modified T lymphocytes produced in (b) or (c).
Assignees
Inventors
Classifications
having 5 to 11 amino acids · CPC title
Genetically modified cells · CPC title
- C07K14/78Primary
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title
against material from animals or humans · CPC title
- C07K14/4748Primary
Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016331818A1 cover?
- The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.
- Who is the assignee on this patent?
- Lopez Marc, Olive Daniel, Inserm (Institut Nat De La Sante Et De La Rech Medicale), and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/78. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Nov 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).